Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 103 | BSPED2024 | Next issue

51st Annual Meeting of the British Society for Paediatric Endocrinology and Diabetes

Glasgow, UK
08 Oct 2024 - 10 Oct 2024

Card image cap
The 51st Annual BSPED Meeting will take place at the Hilton Hotel, Glasgow from Tuesday 8 – Thursday 10 October 2024.

ea0103p76 | Bone 2 | BSPED2024

The acceptability of preventative bisphosphonate therapy prior to fracture: perspectives of young people with duchenne muscular dystrophy, parents/carers and health professionals

Mountain Danielle , Crabtree Nicola , Wood Claire , Wong Sze Choong. , Bray Lucy

Background: Osteoporosis and vertebral fracture development are common in young people with Duchenne muscular dystrophy (DMD) and can lead to chronic back pain and reduced quality of life. The current standards of care recommend initiation of bisphosphonate treatment following identification of fractures. Given the extent of fractures in these young people, initiation of treatment prior to fractures seems logical. This study aimed to explore the opinions of young people with D...

ea0103p77 | Bone 2 | BSPED2024

Parathyroidectomy in paediatric sporadic primary hyperparathyroidism

Prentice Philippa , Oh Han Boon. , Abdel-Aziz Tarek , Butler Colin , Chesover Alexander D. , Brain Caroline , Allgrove Jeremy , Kurzawinski Tom

Introduction: Sporadic primary hyperparathyroidism (sPHPT) is rare in children. There are few large cohorts characterising presentation, investigations and outcomes. Surgical practice is also changing; minimally invasive parathyroidectomy (MIP) and intra-operative parathyroid hormone (IOPTH) monitoring are being performed more frequently.Method: Retrospective casenote review of children with sPHPT who had parathyroidectomy between 1977-2022 at a single t...

ea0103p78 | Bone 2 | BSPED2024

Safety and efficacy of long-term continuous subcutaneous PTH (1-34) infusion therapy (CSPI) for severe autosomal dominant hypocalcaemia type 1 (ADH1) in children and young people

Perogiannaki Aikaterini , Alattar Mohammad Meshari , Baske Kishore , Gorrigan Rebecca J. , Smith Oladimeji , Pullen Debbie , Sankaranarayanan Sailesh , Allgrove Jeremy , Gevers Evelien

Introduction: ADH1, caused by gain of function (GoF) variants in the Calcium Sensing Receptor (CASR), leads to hypoparathyroidism, hypocalcaemia, seizures, hyperphosphatemia, hypomagnesaemia, and severe hypercalciuria. Conventional treatment (alphacalcidol and calcium) can cause nephrocalcinosis, renal impairment and may not reduce seizures. Our previous data on six patients showed that CSPI via insulin pump increases serum calcium and reduces seizures, hospital admis...

ea0103p79 | Bone 2 | BSPED2024

A case of intractable infant hypocalcaemia due to GCM2-mutation linked hypoparathyroidism

Sothyarunasalam Uthayageetha , Makaya Taffy , Basu Supriyo

Introduction: We present a case of severe hypocalcaemia in a 6-week-old baby, secondary to genetic hypoparathyroidism.Case report: A 6-week-old female presented with seizures. She is the first child to non-consanguineous parents of Asian-Pakistani ethnic origin. She was delivered at term and had an uneventful neonatal period. There was no family history of calcium disorders. Blood investigations showed low serum adjusted calcium of 1.26 mmol/l (2.2-2.6 m...

ea0103p80 | Bone 2 | BSPED2024

A late presentation of autosomal dominant hypocalcemia type 1 (ADH1)

Megahed Ahmed , Daskas Nikolaos

Background: The calcium sensing receptor (CaSR) plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone (PTH) secretion and urinary calcium excretion. Autosomal dominant hypocalcaemia type 1 (ADH1) is a disorder of extracellular calcium homeostasis caused by activating germline gain-of-function mutations of the CaSR.Case: A 13-year-old girl was referred from primary care with hypocalcaemia. She was under CAMHS for eating dis...

ea0103p81 | Bone 2 | BSPED2024

Management of prolonged refractory hypercalcaemia secondary to denosumab cessation: a case presentation

McBay-Doherty Rhiannon , McKay Catriona , Heffernan Emmeline

Introduction: We present the case of a 14-year-old boy with refractory hypercalcaemia secondary to Denosumab cessation. This case is unique due to his extensive treatment course and relapse during therapy.Background: Denosumab is a monoclonal antibody used in the treatment of osteoporosis, skeletal metastasis, and giant cell tumour of bone. In skeletally immature patients, studies have proven its effectiveness in suppressing bone resorption and alleviati...

ea0103p82 | Bone 2 | BSPED2024

Cardiovascular risk and achondroplasia: a systematic review

Lo* Irene , Meti* Shraddha , Mason Avril , Lucas-Herald Angela

Introduction: Achondroplasia, caused by a variant in the fibroblast growth factor receptor 3 (FGFR3) gene is the most common form of disproportionate short stature. It is associated with reduced life expectancy, but it is not clear to what extent cardiovascular disease (CVD) is responsible for this. As such, the primary aim of this systematic review was to identify the prevalence of cardiovascular disease in individuals with this condition.Methods: A sys...